Articles

The Use of Chemotherapy in the Metastatic Setting

The Use of Chemotherapy in the Metastatic Setting

By Dr Matthew Goetz

Breast Cancer, SABCS Highlights

Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.

The Mechanism of Action of CDK4/6 Inhibitors

The Mechanism of Action of CDK4/6 Inhibitors

By Dr Matthew Goetz

Breast Cancer, SABCS Highlights

Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.

HER2-Positive Breast Cancer and CDK4/6 Inhibitors

HER2-Positive Breast Cancer and CDK4/6 Inhibitors

By Dr Hope Rugo

Breast Cancer, SABCS Highlights

Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

By Dr Hope Rugo

Breast Cancer, SABCS Highlights

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

By Dr Hope Rugo

Breast Cancer, SABCS Highlights

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

By Dr Hope Rugo

Breast Cancer, SABCS Highlights

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

By Dr Hope Rugo

Breast Cancer, SABCS Highlights

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.

Hot Topics at SABCS 2017

Hot Topics at SABCS 2017

By Dr Hope Rugo

Breast Cancer, SABCS Highlights

Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more.

Opdivo First Immunotherapy Approved for Hepatocellular Carcinoma

FDA Approvals, News & Updates

December 2017, Vol 8, No 5

On September 22, 2017, the FDA granted accelerated approval to nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of hepatocellular carcinoma (HCC)—the most common type of liver cancer—in patients who previously received sorafenib treatment. Opdivo received priority review for this indication.

Identifying Long-Term Unmet Needs in Survivorship Care

By Meg Barbor, MPH

Survivorship, Policies & Guidelines

December 2017, Vol 8, No 5

New Orleans, LA—The number of cancer survivors is increasing. To keep up with this trend, survivorship care must evolve and become more efficient, insists Jennifer R. Klemp, PhD, MPH, MA, Director, Cancer Survivorship, University of Kansas Cancer Center, Westwood. A growing number of patients are living with or through their disease, while the provider workforce is shrinking.

Page 121 of 329